Platform for studying biomarkers and treatments in head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive clinical registry that reflects the real-world treatment landscape for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. It focuses on collecting data related to tumor biomarkers and treatment outcomes, particularly in light of recent advancements such as immune checkpoint inhibitors. The study will link molecular testing results to core data to optimize treatment strategies and provide insights into the management of rare tumor entities. The flexible design allows for the integration of contemporary research questions as they arise.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Able to understand and willing to sign written informed consent
* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
* Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
* Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease

Exclusion Criteria: none

Where it's running

• Onkologie/Studienzentrum am Raschplatz GbR
  Hanover, Germany Recruiting
• Universitätsklinikum Essen
  Essen, Germany Not yet recruiting

Study contacts

• Principal investigator: Michael Pogorzelski, Dr. — Universitätsklinikum Essen
• Study coordinator: Project Manager
• Email: kht-register@aio-studien-ggmbh.de
• Phone: +49 (0)30 814534431

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reducing radiation therapy for head and neck cancer patients

  This study is testing if cutting back on radiation for head and neck cancer patients can help reduce side effects while still keeping the cancer under control.

  Recruiting Phase 2/3 University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT06030440

• Fluorescence-guided surgery to help remove laryngeal and hypopharyngeal cancers

  This trial tests a fluorescent imaging agent to help see cancer tissue during laryngeal and hypopharyngeal cancer surgery in adults.

  Recruiting Phase 2 Erasmus Medical Center · Rotterdam, South Holland and 1 other locations · NCT05752149

• Immune biomarker testing in cisplatin-ineligible head and neck squamous cell cancer patients treated with chemoradiation and docetaxel

  This project will test whether immune markers from tumor tissue, blood, saliva and stool can help predict outcomes and show increased tumor immune activity in people with oropharynx, hypopharynx, larynx or oral cavity squamous cell cancer who can't take cisplatin and are receiving chemoradiation with docetaxel.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT06947668

• Treatment for advanced laryngeal and hypopharyngeal cancer using chemotherapy and immunotherapy

  This study is testing if adding an immune therapy to chemotherapy can help people with advanced throat cancer keep their voice box while improving their chances of survival.

  Recruiting at 5 sites Phase 2 University of Leipzig · Mannheim, Baden-Würtemberg and 8 other locations · NCT06137378

• Finding tissue and blood markers that predict response to immunotherapy in recurrent or metastatic upper throat and mouth squamous cell cancer

  This project will try to find tumor and blood markers that predict whether adults with recurrent or metastatic squamous cell cancer of the oropharynx or nearby upper aerodigestive sites will respond to PD‑1 immunotherapy.

  Recruiting at 2 sites Fondation Hôpital Saint-Joseph · Paris and 2 other locations · NCT06061705

• Lower dose radiation therapy for HPV positive head and neck cancer

  This study is testing if a lower dose of radiation therapy can safely treat HPV positive head and neck cancer while causing fewer side effects.

  Recruiting at 3 sites Phase 2 University of Virginia · Miami, Florida and 4 other locations · NCT05962242

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.